Skip to main content
SpringerLink
Log in
Book cover

Drug Delivery pp 299–341Cite as

Drug-Eluting Medical Implants

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 197))

Abstract

Drug-eluting medical implants are actually active implants that induce healing effects, in addition to their regular task of support. This effect is achieved by controlled release of active pharmaceutical ingredients (API) into the surrounding tissue. In this chapter we focus on three types of drug-eluting devices: drug-eluting vascular stents, drug-eluting wound dressings and protein-eluting scaffolds for tissue regeneration, thus describing both internal and external implants. Each of these drug-eluting devices also presents an approach for solving the drug release issue. Most drug-eluting vascular stents are loaded with water-insoluble antiproliferative agents, and their diffusion from the device to the surrounding tissue is relatively slow. In contrast, most drug-eluting wound dressings are loaded with highly water-soluble antibacterial agents and the issue of fast release must therefore be addressed. Growth factor release from scaffolds for tissue regeneration offers a new approach of incorporating high-molecular-weight bioactive agents which are very sensitive to process conditions and preserve their activity during the preparation stage. The drug-eluting medical implants are described here in terms of matrix formats and polymers, incorporated drugs and their release profiles from the implants, and implant functioning. Basic elements, such as new composite core/shell fibers and structured films, can be used to build new antibiotic-eluting devices. As presented in this chapter, the effect of the processing parameters on the microstructure and the resulting drug release profiles, mechanical and physical properties, and other relevant properties, must be elucidated in order to achieve the desired properties. Newly developed implants and novel modifications of previously developed approaches have enhanced the tools available for creating clinically important biomedical applications.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB (2007) Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. Am J Cardiol 99:1403–1408

    CAS  PubMed  Google Scholar 

  • Alexis, F., et al., (2004) In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 98(1):67–74

    Google Scholar 

  • Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N (2005a) Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 46:1670–1676

    PubMed  Google Scholar 

  • Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJ (2005b) Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45:1574–1579

    CAS  PubMed  Google Scholar 

  • Aoyagi S, Onishi H, Machida Y (2007) Novel chitosan wound dressing loaded with minocycline for the treatment of severe burn wounds. Int J Pharm 330:138–145

    CAS  PubMed  Google Scholar 

  • Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA (2004) Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. J Am Med Assoc 292:2727–2734

    CAS  PubMed  Google Scholar 

  • Babapulle MN, Eisenberg MJ (2002) Coated stents for the prevention of restenosis: part II. Circulation 106:2859–2866

    PubMed  Google Scholar 

  • Babensee JE, McIntire LV, Mikos AG (2000) Growth factor delivery for tissue engineering. Pharm Res 17:497–504

    CAS  PubMed  Google Scholar 

  • Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO (2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. J Am Med Assoc 297:1992–2000

    CAS  PubMed  Google Scholar 

  • Berg R, Aragon J, Royter V, Shanley JF, Cogert G, Vermani R, Kar S, Eigler N, Litvack F (2007) Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. Catheter Cardiovasc Interv 70:871–879

    PubMed  Google Scholar 

  • Buchbinder M (2007) Biodegradable stents: BTI approach. Foundation for Cardiovascular Medicine, www.summitmd.com/pdf/pdf/070601_7.pdf

  • Buket Basmanav F, Kose GT, Hasirci V (2008) Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials 29:4195–4204

    CAS  PubMed  Google Scholar 

  • Cairns BA, deSerres S, Peterson HD, Meyer AA (1993) Skin replacements. The biotechnological quest for optimal wound closure. Arch Surg 128:1246–1252

    CAS  PubMed  Google Scholar 

  • Chang HI, Lau YC, Yan C, Coombes AG (2008) Controlled release of an antibiotic, gentamicin sulphate, from gravity spun polycaprolactone fibers. J Biomed Mater Res A 84:230–237

    PubMed  Google Scholar 

  • Chen RR, Mooney DJ (2003) Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 20:1103–1112

    CAS  PubMed  Google Scholar 

  • Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D (2007) Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. Euro Intervention 2:426–434

    PubMed  Google Scholar 

  • Chorny M, Fishbein I, Golomb G (2000) Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 17:249–284

    CAS  PubMed  Google Scholar 

  • Chung LY, Schmidt RJ, Hamlyn PF, Sagar BF, Andrews AM, Turner TD (1994) Biocompatibility of potential wound management products: fungal mycelia as a source of chitin/chitosan and their effect on the proliferation of human F1000 fibroblasts in culture. J Biomed Mater Res 28:463–469

    CAS  PubMed  Google Scholar 

  • Colletta V, Dioguardi D, Di Lonardo A, Maggio G, Torasso F (2003) A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. J Wound Care 12:357–360

    CAS  PubMed  Google Scholar 

  • Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788–794

    CAS  PubMed  Google Scholar 

  • Commandeur S, van Beusekom HM, van der Giessen WJ (2006) Polymers, drug release, and drug-eluting stents. J Interv Cardiol 19:500–506

    PubMed  Google Scholar 

  • Corporation BS (2007) TAXUS IV final 5-year outcomes, taken from Boston Scientific web site: www.bostonscientific.com, Boston Scientific Corporation

  • Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition. Circ Res 86:879–884

    CAS  PubMed  Google Scholar 

  • Daemen J, Ong AT, Stefanini GG, Tsuchida K, Spindler H, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW (2006) Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98:895–901

    CAS  PubMed  Google Scholar 

  • Daemen J, Serruys PW (2007) Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 116:316–328

    PubMed  Google Scholar 

  • Dawkins K, Verheye S, Schühlen H, Dens J, Mudra H, Rutsch W, Stella P, Di Mario C, Thomas M, Serruys PW, Colombo A (2007) The European cobalt STent with antiproliferative for restenosis trial (EuroSTAR): 12 month results. Eur Heart J 3:82–88

    Google Scholar 

  • Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME (2005) Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112:3306–3313

    CAS  PubMed  Google Scholar 

  • Duda SH, Poerner TC, Wiesinger B, Rundback JH, Tepe G, Wiskirchen J, Haase KK (2003) Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 14:291–301

    PubMed  Google Scholar 

  • Eisinger M, Lee JS, Hefton JM, Darzynkiewicz Z, Chiao JW, de Harven E (1979) Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements. Proc Natl Acad Sci USA 76:5340–5344

    CAS  PubMed  Google Scholar 

  • Elcin AE, Elcin YM (2006) Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA sponge. Tissue Eng 12:959–968

    CAS  PubMed  Google Scholar 

  • Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A (1998) Vessel size and long-term outcome after coronary stent placement. Circulation 98:1875–1880

    CAS  PubMed  Google Scholar 

  • Elsner JJ, Zilberman M (2009) Antibiotic-eluting bioresorbable composite fibers for wound healing applications: microstructure, drug delivery and mechanical properties. Acta Biomater 5:2872–2883

    Google Scholar 

  • Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE (2006) Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114:798–806

    CAS  PubMed  Google Scholar 

  • Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99:44–52

    CAS  PubMed  Google Scholar 

  • Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115:2435–2441

    PubMed  Google Scholar 

  • Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovish A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 331:496–501

    CAS  PubMed  Google Scholar 

  • Foye WO, Lemke TL, Williams DA (1998) Principles of medicinal chemistry, 3rd edn. Lea & Febiger, Baltimore, MD

    Google Scholar 

  • Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM (2004) An in vitro study of the anti-microbial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulphadiazine cream and a silver coated dressing. Burns 30:35–41

    PubMed  Google Scholar 

  • Freed M, Safian RD, Grines C (1996) Manual of interventional cardiology. Physicians’ Press, Birmingham, MI

    Google Scholar 

  • Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, Gai LY, Ge JB, Wang WM, Du ZM, Huo Y, Wang LF, Gao W, Chen JY, He B, Jia GL, Yang ZJ, Cao KJ, Li WM, Shen WF, Wan Z, Huang DJ, Zhu GY (2008) Safety and efficacy of the CYPHER select sirolimus-eluting stent in the “Real World”–clinical and angiographic results from the China CYPHER select registry. Int J Cardiol 125:339–346

    PubMed  Google Scholar 

  • George J, Sack J, Barshack I, Keren P, Goldberg I, Haklai R, Elad-Sfadia G, Kloog Y, Keren G (2004) Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. Arterioscler Thromb Vasc Biol 24:363–368

    CAS  PubMed  Google Scholar 

  • Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW (2004) Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109:487–493

    CAS  PubMed  Google Scholar 

  • Gershlick AH (2005) Drug eluting stents in 2005. Heart 91(Suppl 3):iii24–iii31

    CAS  PubMed  Google Scholar 

  • Gold HS, Moellering RC Jr (1996) Antimicrobial-drug resistance. N Engl J Med 335:1445–1453

    CAS  PubMed  Google Scholar 

  • Gransden WR (1997) Antibiotic resistance. Nosocomial gram-negative infection. J Med Microbiol 46:436–439

    CAS  PubMed  Google Scholar 

  • Grinberg O (2007) Highly porous bioresorbable scaffolds with controlled release of bioactive agents for tissue regeneration applications. MSc thesis. Tel Aviv University

    Google Scholar 

  • Gristina AG (1987) Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237:1588–1595

    CAS  PubMed  Google Scholar 

  • Grube E (2008) Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. Eur Heart J 4:71–76

    Google Scholar 

  • Grube E, Bullesfeld L (2002) Initial experience with paclitaxel-coated stents. J Interv Cardiol 15:471–475

    PubMed  Google Scholar 

  • Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109:2168–2171

    CAS  PubMed  Google Scholar 

  • Halkin A, Stone GW (2004) Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 17:271–282

    PubMed  Google Scholar 

  • Heggers J, Goodheart RE, Washington J, McCoy L, Carino E, Dang T, Edgar P, Maness C, Chinkes D (2005) Therapeutic efficacy of three silver dressings in an infected animal model. J Burn Care Rehabil 26:53–56

    PubMed  Google Scholar 

  • Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289–2295

    CAS  PubMed  Google Scholar 

  • Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27:166–170

    PubMed  Google Scholar 

  • Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:634–640

    PubMed  Google Scholar 

  • Howard D, Buttery LD, Shakesheff KM, Roberts SJ (2008) Tissue engineering: strategies, stem cells and scaffolds. J Anat 213:66–72

    CAS  PubMed  Google Scholar 

  • Hutchinson FG, Furr BJ (1985) Biodegradable polymers for the sustained release of peptides. Biochem Soc Trans 13:520–523

    CAS  PubMed  Google Scholar 

  • Ignatova M, Starbova K, Markova N, Manolova N, Rashkov I (2006) Electrospun nano-fibre mats with antibacterial properties from quaternised chitosan and poly(vinyl alcohol). Carbohydr Res 341:2098–2107

    CAS  PubMed  Google Scholar 

  • Iofina E, Langenberg R, Blindt R, Kuhl H, Kelm M, Hoffmann R (2006) Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 98:1022–1027

    CAS  PubMed  Google Scholar 

  • Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202

    PubMed  Google Scholar 

  • Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333–342

    CAS  PubMed  Google Scholar 

  • Jones SA, Bowler PG, Walker M, Parsons D (2004) Controlling wound bioburden with a novel silver-containing hydrofiber dressing. Wound Repair Regen 12:288–294

    PubMed  Google Scholar 

  • Jürgens C, Schulz AP, Porté T, Faschingbauer M, Seide K (2006) Biodegradable films in trauma and orthopedic surgery. Eur J Trauma 2:160–171

    Google Scholar 

  • Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428–1436

    CAS  PubMed  Google Scholar 

  • Katti DS, Robinson KW, Ko FK, Laurencin CT (2004) Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater 70:286–296

    Google Scholar 

  • Kau U (2007) CObalt Chromium STent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart J 59:167–172

    Google Scholar 

  • Kloog Y, Cox AD (2004) Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 14:253–261

    CAS  PubMed  Google Scholar 

  • Knill CJ, Kennedy JF, Mistry J, Miraftab M, Smart G, Groocock MR, Williams HJ (2004) Alginate fibres modified with unhydrolysed and hydrolysed chitosans for wound dressings. Carbohydr Polym 55:65–76

    CAS  Google Scholar 

  • Kraitzer A, Kloog Y, Zilberman M (2007) Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 85B:583–603

    Google Scholar 

  • Kraitzer A, Kloog Y, Zilberman M (2009) Novel farnesylthiosalicylate (FTS)-eluting composite structures. Eur J Pharm Sci 37:351–362

    Google Scholar 

  • Kraitzer A, Ofek L, Schreiber R, Zilberman M (2008) Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures. J Control Release 126:139–148

    CAS  Google Scholar 

  • Kraitzer A, Zilberman M (2007) Paclitaxel-loaded composite fibers: microstructure and emulsion stability. J Biomed Mater Res A 81:427–436

    PubMed  Google Scholar 

  • Kraitzer A, Zilberman M (2009) Novel Farnesylthiosalicylate (FTS) –Eluting Composite Structures. J Control Release 37(3–4):351–362

    CAS  Google Scholar 

  • Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O’Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W (2008) A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 51:1543–1552

    CAS  PubMed  Google Scholar 

  • Kutryk MJ (2003) Drug eluting stents for the treatment of coronary artery disease part 4: New results from clinical trials and future directions, Cardiology Rounds VIII, issue 10

    Google Scholar 

  • Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019

    CAS  PubMed  Google Scholar 

  • Langer R, Vacanti JP (1993) Tissue engineering. Science 260:920–926

    CAS  PubMed  Google Scholar 

  • Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O’Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O’Neill WW (2004) Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109:1948–1954

    CAS  PubMed  Google Scholar 

  • Lee SH, Szinai I, Carpenter K, Katsarava R, Jokhadze G, Chu CC, Huang Y, Verbeken E, Bramwell O, De Scheerder I, Hong MK (2002) In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coron Artery Dis 13:237–241

    CAS  PubMed  Google Scholar 

  • Lewis AL, Tolhurst LA, Stratford PW (2002) Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 23:1697–1706

    CAS  PubMed  Google Scholar 

  • Lincoff A.M, et al (1997) Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29:808–816

    Google Scholar 

  • Liu X, Huang Y, Hanet C, Vandormael M, Legrand V, Dens J, Vandenbossche JL, Missault L, Vrints C, De Scheerder I (2003) Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 60:172–178 discussion 179

    PubMed  Google Scholar 

  • Maruguchi T, Maruguchi Y, Suzuki S, Matsuda K, Toda K, Isshiki N (1994) A new skin equivalent: keratinocytes proliferated and differentiated on collagen sponge containing fibroblasts. Plast Reconstr Surg 93:537–544 Discussion 545-6

    CAS  PubMed  Google Scholar 

  • Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029

    CAS  PubMed  Google Scholar 

  • Medsystems C (2007) Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions. Johnson & Johnson press release

    Google Scholar 

  • Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ, Cutlip DE, Fitzgerald PJ (2007a) Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 100:56M–61M

    CAS  PubMed  Google Scholar 

  • Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P (2007b) The next-generation Endeavor™ Resolute™ stent: 4-month clinical and angiographic results from the Resolute™ first-in-man trial. Euro Intervention 3:50–53

    PubMed  Google Scholar 

  • Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, Hao JY (2002) Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 59:438–449

    CAS  PubMed  Google Scholar 

  • Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AH, Kandzari DE, Honda Y, Fitzgerald PJ (2008) Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 155:108–113

    CAS  PubMed  Google Scholar 

  • Moreno R, Macaya C (2005) Stent-based delivered anti-proliferative drugs in the prevention of coronary stent restenosis. Curr Med Chem Cardiovasc Hematol Agents 3:221–229

    CAS  PubMed  Google Scholar 

  • Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. J Am Med Assoc 295:895–904

    CAS  PubMed  Google Scholar 

  • Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E (2007) Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50:1299–1304

    CAS  PubMed  Google Scholar 

  • Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780

    CAS  PubMed  Google Scholar 

  • Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323

    CAS  PubMed  Google Scholar 

  • Muzzarelli R, Tarsi R, Filippini O, Giovanetti E, Biagini G, Varaldo PE (1990) Antimicrobial properties of N-carboxybutyl chitosan. Antimicrob Agents Chemother 34:2019–2023

    CAS  PubMed Central  PubMed  Google Scholar 

  • Nguyen KT, Su SH, Zilberman M, Bohluli P, Frenkel P, Tang L, Eberhart RC (2004) Biomaterials and stent technology. In: Yaszemski M, Rantolo D, Lewandrowski KU, Hasirci V, Altobelli D, Wise D (eds) Tissue engineering and novel delivery systems. Marcel Dekker, New York, pp 107–130

    Google Scholar 

  • Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899–907

    CAS  PubMed  Google Scholar 

  • Ostojik M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D (2008) First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. Euro Intervention 3:574–579

    Google Scholar 

  • Park SN, Kim JK, Suh H (2004) Evaluation of antibiotic-loaded collagen-hyaluronic acid matrix as a skin substitute. Biomaterials 25:3689–3698

    CAS  PubMed  Google Scholar 

  • Peterson L (2004) PARIS COURSE ON REVASCULARIZATION (PCR) Trends-in-Medicine. Stephen Snyder, Paris, France

    Google Scholar 

  • Planer D, Beyar R, Almagor Y, Banai S, Guetta V, Miller H, Kornowski R, Brandes S, Krakover R, Solomon M, Lotan C (2008) Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am J Cardiol 101:953–959

    CAS  PubMed  Google Scholar 

  • Popma JJ (2007) Stent Design, Materials, Polymers and Drugs for DES

    Google Scholar 

  • Prabu P, Dharmaraj N, Aryal S, Lee BM, Ramesh V, Kim HY (2006) Preparation and drug release activity of scaffolds containing collagen and poly(caprolactone). J Biomed Mater Res A 79:153–158

    CAS  PubMed  Google Scholar 

  • Price JS, Tencer AF, Arm DM, Bohach GA (1996) Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res 30:281–286

    CAS  PubMed  Google Scholar 

  • Pruitt BA Jr, Levine NS (1984) Characteristics and uses of biologic dressings and skin substitutes. Arch Surg 119:312–322

    PubMed  Google Scholar 

  • Radu FA, Bause M, Knabner P, Lee GW, Friess WC (2002) Modeling of drug release from collagen matrices. J Pharm Sci 91:964–972

    CAS  PubMed  Google Scholar 

  • Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW (2008) Postmarket evaluation of breakthrough technologies. Am Heart J 156:201–208

    PubMed  Google Scholar 

  • Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED (2006) On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97:1478–1481

    CAS  PubMed  Google Scholar 

  • REVA Medical I (2007) REVA Medical Announces Enrollment of First Patients in the RESORB Clinical Trial

    Google Scholar 

  • Revathi G, Puri J, Jain BK (1998) Bacteriology of burns. Burns 24:347–349

    CAS  PubMed  Google Scholar 

  • Ribichini F, Tomai F, Paloscia L, Di Sciascio G, Carosio G, Romano M, Verna E, Galli M, Tamburino C, De Cesare N, Pirisi R, Piscione F, Lanteri G, Ferrero V, Vassanelli C (2007) Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart 93:598–600

    PubMed  Google Scholar 

  • Roenigk RK, Roenigk HH (1989) Dermatologic surgery: principles and practice. M. Dekker, New York

    Google Scholar 

  • Rogers CD (2004) Optimal stent design for drug delivery. Rev Cardiovasc Med 5(Suppl 2):S9–S15

    PubMed  Google Scholar 

  • Rossi S, Marciello M, Sandri G, Ferrari F, Bonferoni MC, Papetti A, Caramella C, Dacarro C, Grisoli P (2007) Wound dressings based on chitosans and hyaluronic acid for the release of chlorhexidine diacetate in skin ulcer therapy. Pharm Dev Technol 12:415–422

    CAS  PubMed  Google Scholar 

  • Roy P, Bonello L, de Labriolle A, Okabe T, Pinto Slottow TL, Steinberg DH, Torguson R, Smith K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R (2008) Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 102:292–297

    CAS  PubMed  Google Scholar 

  • Ruszczak Z, Friess W (2003) Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev 55:1679–1698

    CAS  PubMed  Google Scholar 

  • Saito Y, Minami K, Kobayashi M, Nakao Y, Omiya H, Imamura H, Sakaida N, Okamura A (2002) New tubular bioabsorbable knitted airway stent: biocompatibility and mechanical strength. J Thorac Cardiovasc Surg 123:161–167

    PubMed  Google Scholar 

  • Salam AM, Al Suwaidi J, Holmes DR Jr (2006) Drug-eluting coronary stents. Curr Probl Cardiol 31:8–119

    PubMed  Google Scholar 

  • Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43:1110–1115

    CAS  PubMed  Google Scholar 

  • Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093–1099

    CAS  PubMed  Google Scholar 

  • Serruys P (2005) Randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Eur Heart J 1:58–65

    Google Scholar 

  • Serruys P (2006) Randomized comparison of an everolimus eluting coronary stent with a paclitaxel eluting coronary stent: the SPIRIT II trial. Eur Heart J 2:286–294

    Google Scholar 

  • Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495

    CAS  PubMed  Google Scholar 

  • Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F (2005) The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46:253–260

    CAS  PubMed  Google Scholar 

  • Shanmugasundaram N, Sundaraseelan J, Uma S, Selvaraj D, Babu M (2006) Design and delivery of silver sulfadiazine from alginate microspheres-impregnated collagen scaffold. J Biomed Mater Res B Appl Biomater 77:378–388

    CAS  PubMed  Google Scholar 

  • Sousa JE, Serruys PW, Costa MA (2003a) New frontiers in cardiology: drug-eluting stents: part I. Circulation 107:2274–2279

    PubMed  Google Scholar 

  • Sousa JE, Serruys PW, Costa MA (2003b) New frontiers in cardiology: drug-eluting stents: part II. Circulation 107:2383–2389

    PubMed  Google Scholar 

  • Springer BD, Lee GC, Osmon D, Haidukewych GJ, Hanssen AD, Jacofsky DJ (2004) Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. Clin Orthop Relat Res 427:47–51

    PubMed  Google Scholar 

  • Sripriya R, Kumar MS, Sehgal PK (2004) Improved collagen bilayer dressing for the controlled release of drugs. J Biomed Mater Res B Appl Biomater 70:389–396

    PubMed  Google Scholar 

  • Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP, Tcheng JE, Greenfield JC Jr (1988) Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 62:3F–24F

    CAS  PubMed  Google Scholar 

  • Stella PR et al (2008) One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. Eur Heart J 4(2):200–207

    Google Scholar 

  • Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947

    CAS  PubMed  Google Scholar 

  • Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. J Am Med Assoc 299:1903–1913

    CAS  PubMed  Google Scholar 

  • Sussman C, Bates-Jensen BM (2001) Wound care: a collaborative practice manual for physical therapists and nurses, 2nd edn. Aspen Publishers, Gaithersburg, Md

    Google Scholar 

  • Suzuki Y, Tanihara M, Nishimura Y, Suzuki K, Kakimaru Y, Shimizu Y (1997) A novel wound dressing with an antibiotic delivery system stimulated by microbial infection. Asaio J 43:M854–M857

    CAS  PubMed  Google Scholar 

  • Suzuki Y, Tanihara M, Nishimura Y, Suzuki K, Kakimaru Y, Shimizu Y (1998) A new drug delivery system with controlled release of antibiotic only in the presence of infection. J Biomed Mater Res 42:112–116

    CAS  PubMed  Google Scholar 

  • Taddeucci P, Pianigiani E, Colletta V, Torasso F, Andreassi L, Andreassi A (2004) An evaluation of Hyalofill-F plus compression bandaging in the treatment of chronic venous ulcers. J Wound Care 13:202–204

    CAS  PubMed  Google Scholar 

  • Tamai H, Igaki K, Tsuji T (1999) A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J Intervent Cardiol 12:443–449

    Google Scholar 

  • Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404

    CAS  PubMed  Google Scholar 

  • Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME (2003) TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107:559–564

    PubMed  Google Scholar 

  • Tepe G, Wendel HP, Khorchidi S, Schmehl J, Wiskirchen J, Pusich B, Claussen CD, Duda SH (2002) Thrombogenicity of various endovascular stent types: an in vitro evaluation. J Vasc Interv Radiol 13:1029–1035

    PubMed  Google Scholar 

  • Trafny EA, Kowalska K, Grzybowski J (1998) Adhesion of Pseudomonas aeruginosa to collagen biomaterials: effect of amikacin and ciprofloxacin on the colonization and survival of the adherent organisms. J Biomed Mater Res 41:593–599

    CAS  PubMed  Google Scholar 

  • Trop M (2006) Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 61:1024

    PubMed  Google Scholar 

  • Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Muller R, Storger H, Hauptmann KE, Grube E (2006) Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 98:464–469

    CAS  PubMed  Google Scholar 

  • Turco MA, Ormiston JA, Popma JJ, Mandinov L, O’Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J (2007) Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 49:1676–1683

    CAS  PubMed  Google Scholar 

  • Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: 1-year follow-up of the e-Cypher registry. Circulation 113:1434–1441

    CAS  PubMed  Google Scholar 

  • Uurto I et al (2005) Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. J Endovasc Ther 12(3):371–379

    Google Scholar 

  • Varghese MC, Balin AK, Carter DM, Caldwell D (1986) Local environment of chronic wounds under synthetic dressings. Arch Dermatol 122:52–57

    CAS  PubMed  Google Scholar 

  • Venkatraman S, Boey F (2007) Release profiles in drug-eluting stents: issues and uncertainties. J Control Release 120:149–160

    CAS  Google Scholar 

  • Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705

    PubMed  Google Scholar 

  • Vogt F et al (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340

    Google Scholar 

  • Vranckx P, Serruys PW, Gambhir S, Eduardo SJ, Abizaid A, Lemos P, Ribeiro E, Dani SI, Dalal JJ, Mehan V, Dhar A, Dutta AL, Reddy KN, Chand R, Ray A (2006) Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. Euro Intervention 2:310–317

    CAS  PubMed  Google Scholar 

  • Waksman R (2006) Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol 19:414–421

    PubMed  Google Scholar 

  • Wang X, Venkatraman SS, Boey FY, Loo JS, Tan LP (2006) Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 27:5588–5595

    CAS  PubMed  Google Scholar 

  • Wei G, Jin Q, Giannobile WV, Ma PX (2006) Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 112:103–110

    Google Scholar 

  • Whang K, Thomas CH, Healy KE and Nuber G. (1995) A novel method to fabricate bioabsorbable scaffolds. Polymer 36:837–842

    Google Scholar 

  • Whang K, Tsai DC, Nam EK, Aitken M, Sprague SM, Patel PK and Healy KE (1998) Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mat Res 42:491–499

    Google Scholar 

  • Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372:1163–1173

    CAS  PubMed  Google Scholar 

  • Woods TC, Marks AR (2004) Drug-eluting stents. Annu Rev Med 55:169–178

    CAS  PubMed  Google Scholar 

  • Wu P, Grainger DW (2006) Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 27:2450–2467

    CAS  PubMed  Google Scholar 

  • Xu RX, Sun X, Weeks BS (2004) Burns regenerative medicine and therapy. Karger, Basel

    Google Scholar 

  • Yamawaki T et al (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786

    Google Scholar 

  • Ye YW et al (1998) Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 26:398–408

    Google Scholar 

  • Zalavras CG, Patzakis MJ, Holtom P (2004) Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res 427:86–93

    PubMed  Google Scholar 

  • Zhu XH, Wang CH, Tong YW (2008) In vitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold. J Biomed Mater Res A 89(2):411–423

    Google Scholar 

  • Zidar J, Lincoff A, Stack R (1999) Biodegradable stents. In: Topol EJ (ed) Textbook of interventional cardiology, 3rd edn. WB Saunders, Philadelphia, pp 787–802

    Google Scholar 

  • Zilberman M, Golerkansky E, Elsner JJ, Berdicevsky I (2009) Gentamicin-eluting bioresorbable composite fibers for wound healing applications. J Biomed Mater Res A 89:654–666

    PubMed  Google Scholar 

  • Zilberman M, Schwade ND, Eberhart RC (2004) Protein-loaded bioresorbable fibers and expandable stents: mechanical properties and protein release. J Biomed Mater Res B Appl Biomater 69:1–10

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Biomedical Engineering, Faculty of Engineering, Tel-Aviv University, Tel-Aviv, 69978, Israel

    Meital Zilberman

Authors
  1. Meital Zilberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Kraitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orly Grinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan J. Elsner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meital Zilberman .

Editor information

Editors and Affiliations

  1. FB Biologie, Chemie, Pharmazie, Inst. Pharmazie, FU Berlin, Königin-Luise-Str. 2-4, Berlin, 14195, Berlin, Germany

    Monika Schäfer-Korting

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zilberman, M., Kraitzer, A., Grinberg, O., Elsner, J.J. (2010). Drug-Eluting Medical Implants. In: Schäfer-Korting, M. (eds) Drug Delivery. Handbook of Experimental Pharmacology, vol 197. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00477-3_11

Download citation

Publish with us

Policies and ethics

Search

Navigation